Summit Therapeutics, Inc. (SMMT)
12.72
-0.44
(-3.31%)
USD |
NASDAQ |
Aug 24, 16:00
12.72
0.00 (0.00%)
After-Hours: 20:00
Summit Therapeutics Shareholders Equity (Quarterly) : 629.98M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 629.98M |
| March 31, 2026 | 545.93M |
| December 31, 2025 | 658.86M |
| September 30, 2025 | 192.26M |
| June 30, 2025 | 259.44M |
| March 31, 2025 | 344.33M |
| December 31, 2024 | 388.75M |
| September 30, 2024 | 437.92M |
| June 30, 2024 | 195.08M |
| March 31, 2024 | 44.21M |
| December 31, 2023 | 77.69M |
| September 30, 2023 | 99.38M |
| June 30, 2023 | 119.60M |
| March 31, 2023 | 133.48M |
| December 31, 2022 | 126.65M |
| September 30, 2022 | 133.25M |
| June 30, 2022 | 51.32M |
| March 31, 2022 | 64.41M |
| December 31, 2021 | 83.28M |
| September 30, 2021 | 102.30M |
| June 30, 2021 | 119.43M |
| March 31, 2021 | 64.40M |
| December 31, 2020 | 79.45M |
| September 30, 2020 | 36.86M |
| Date | Value |
|---|---|
| June 30, 2020 | |
| March 31, 2020 | 67.62M |
| January 31, 2020 | |
| October 31, 2019 | |
| July 31, 2019 | |
| April 30, 2019 | |
| January 31, 2019 | 55.96M |
| October 31, 2018 | 35.82M |
| July 31, 2018 | 43.36M |
| April 30, 2018 | 58.59M |
| January 31, 2018 | -4.528M |
| October 31, 2017 | 21.39M |
| July 31, 2017 | 4.614M |
| April 30, 2017 | -10.32M |
| January 31, 2017 | -4.394M |
| October 31, 2016 | 1.330M |
| July 31, 2016 | 14.03M |
| April 30, 2016 | 23.92M |
| January 31, 2016 | 29.98M |
| October 31, 2015 | 40.02M |
| July 31, 2015 | 47.15M |
| April 30, 2015 | 52.05M |
| January 31, 2015 | 22.48M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| NovelStem International Corp. | -2.032M |
| Brainstorm Cell Therapeutics, Inc. | -11.60M |
| Kezar Life Sciences, Inc. | 65.24M |
| Protara Therapeutics, Inc. | 161.31M |
| Clene, Inc. | -24.78M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 752.18M |
| Total Liabilities (Quarterly) | 122.20M |
| Debt to Equity Ratio | 0.0324 |
| Current Ratio | 6.958 |
| Net Debt Paydown Yield | -0.02% |